Memantine Hydrochloride Crescent Pharma (Memantine Hydrochloride)

The drug acts as a non‑competitive antagonist of the NMDA receptor. By blocking the receptor’s ion channel, it reduces excessive calcium influx that can lead to neuronal injury, thereby limiting excitotoxicity and supporting neuronal health in the brain.

The dosage of Memantine Hydrochloride is individualized by the prescribing clinician based on the patient’s condition, renal function, and tolerability. The prescriber determines the appropriate starting dose and titration schedule.

Safety data for Memantine Hydrochloride in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, so it should only be used if the potential benefit justifies the potential risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA‑receptor antagonist class, whereas many other Alzheimer’s agents are acetylcholinesterase inhibitors (e.g., donepezil). Memantine is typically used in moderate to severe stages and may be combined with an acetylcholinesterase inhibitor for additive benefit, while having a distinct side‑effect profile.

Store the tablets at temperatures below 25 °C in their original container, protected from moisture and direct sunlight. Do not expose the product to excessive heat or humidity, and keep it out of reach of children.

Memantine Hydrochloride is taken orally, usually as a tablet. The patient swallows the tablet whole with water, and dosing is typically once or twice daily as directed by the prescriber.

Serious risks include seizures, cardiac arrhythmias, severe allergic reactions, and neuro‑psychiatric events such as hallucinations or suicidal thoughts. Patients should be monitored closely for any new or worsening symptoms, especially during dose adjustments.

Memantine is contraindicated in patients with known hypersensitivity to the drug. Caution is advised for individuals with severe renal impairment, uncontrolled hypertension, or a history of seizures, and it should be avoided in combination with other NMDA antagonists.